• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Dips Over 100 Points; GameStop Shares Spike higher

    5/28/24 12:00:17 PM ET
    $APDN
    $CALT
    $GME
    $INSM
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APDN alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Tuesday.

    The Dow traded down 0.36% to 38,928.04 while the NASDAQ rose 0.48% to 17,001.83. The S&P 500 also rose, gaining, 0.04% to 5,306.91.

    Check This Out: This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

    Leading and Lagging Sectors

    Information technology shares jumped by 1.2% on Tuesday.

    In trading on Tuesday, health care shares fell by 1.2%.

    Top Headline

    Shares of GameStop Corp. (NYSE:GME) jumped around 24% on Tuesday after the company announced late Friday that it had completed its previously disclosed "at-the-market" (ATM) equity offering, selling a maximum of 45 million common shares.

    The company raised approximately $933.4 million in gross proceeds, which it intends to use for general corporate purposes, including potential acquisitions and investments.

    Equities Trading UP
                           

    • Insmed Incorporated (NASDAQ:INSM) shares shot up 112% to $46.62 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint.
    • Shares of Calliditas Therapeutics AB (NASDAQ:CALT) got a boost, surging 75% to $38.10 after the company’s board recommended the acceptance of Asahi Kasei’s tender offer.
    • Pineapple Energy Inc. (NASDAQ:PEGY) shares were also up, gaining 83% to $0.3259 after the company on Friday announced its SUNation subsidiary signed a 1.95-megawatt project.

    Equities Trading DOWN

    • Applied DNA Sciences, Inc. (NASDAQ:APDN) shares dropped 68% to $0.64 after the company reported the pricing of $12 million public offering.
    • Shares of Marpai, Inc.  (NASDAQ:MRAI) were down 56% to $0.8515 after the company announced its intention to withdraw from the Nasdaq hearings process.
    • Netcapital Inc. (NASDAQ:NCPL) was down, falling 24% to $0.1463 after the company announced that it entered into definitive agreement for the immediate exercise of $2.2 million of certain outstanding Series A-2 warrants.

    Also Check This Out: Top 5 Real Estate Stocks That Could Lead To Your Biggest Gains This Month

    Commodities

    In commodity news, oil traded up 2.3% to $79.50 while gold traded up 1% at $2,357.70.

    Silver traded up 5.3% to $32.10 on Tuesday, while copper rose 1.5% to $4.8260.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.68%, Germany's DAX slipped 0.59% and France's CAC 40 declined 1.03%. Spain's IBEX 35 Index fell 0.64%, while London's FTSE 100 declined 0.85%.

    German wholesale prices fell by 1.8% year-over-year in April compared to a revised 2.6% decline a month ago.

    Asia Pacific Markets

    Asian markets closed lower on Tuesday, with Japan's Nikkei falling 0.11%, China's Composite Index declining 0.46%, Hong Kong's Hang Seng Index falling 0.03% and India's S&P BSE Sensex falling 0.2%.

    Producer prices in Malaysia rose by 1.9% year-over-year in April compared to a 1.6% increase in the earlier month.

    Economics

    • The S&P CoreLogic Case-Shiller home price index rose by 7.4% year-over-year in March versus 7.3% in the previous month.
    • The FHFA house price index rose by 0.1% in March, compared to market expectations of a 0.5% gain.
    • The Federal Reserve Bank of Dallas’ general business activity index for manufacturing in Texas fell to a reading of -19.4 in May, compared to -14.5 a month ago.

    Now Read This: How To Earn $500 A Month From Heico Stock Ahead Of Q2 Earnings

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $CALT
    $GME
    $INSM

    CompanyDatePrice TargetRatingAnalyst
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    Insmed Incorporated
    $INSM
    12/19/2025$202.00Buy
    Truist
    Insmed Incorporated
    $INSM
    12/4/2025$263.00Buy
    Rothschild & Co Redburn
    Insmed Incorporated
    $INSM
    10/28/2025$192.00Overweight
    Cantor Fitzgerald
    Insmed Incorporated
    $INSM
    10/20/2025$171.00Overweight
    Wells Fargo
    Insmed Incorporated
    $INSM
    8/20/2025Outperform
    William Blair
    Insmed Incorporated
    $INSM
    8/13/2025$126.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $APDN
    $CALT
    $GME
    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Insmed with a new price target

    Barclays initiated coverage of Insmed with a rating of Overweight and set a new price target of $231.00

    1/28/26 7:17:09 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Insmed with a new price target

    Roth Capital initiated coverage of Insmed with a rating of Buy and set a new price target of $212.00

    1/23/26 8:19:26 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Insmed with a new price target

    Truist resumed coverage of Insmed with a rating of Buy and set a new price target of $202.00

    12/19/25 8:48:21 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $GME
    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcgirr David W J gifted 53,400 shares and received a gift of 53,400 shares, decreasing direct ownership by 55% to 44,323 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/11/26 4:43:08 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,979,764 worth of shares (13,396 units at $147.79), decreasing direct ownership by 0.89% to 301,185 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/11/26 4:42:22 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Flammer Martina M.D. sold $132,470 worth of shares (869 units at $152.44), decreasing direct ownership by 1% to 83,243 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    2/6/26 4:18:50 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $GME
    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $GME
    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

    BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 19, 2026. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, February 19, 2026, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) an

    2/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

    —Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmonary Arterial Hypertension (PAH), and Pulmonary Vasodilation Data in Rat Models— BRIDGEWATER, N.J., Jan. 28, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dub

    1/28/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $APDN
    $CALT
    $GME
    $INSM
    SEC Filings

    View All

    SEC Form 8-K filed by Netcapital Inc.

    8-K - Netcapital Inc. (0001414767) (Filer)

    2/6/26 4:30:23 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    2/5/26 5:12:15 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-1/A filed by Netcapital Inc.

    S-1/A - Netcapital Inc. (0001414767) (Filer)

    2/2/26 4:05:46 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $APDN
    $CALT
    $GME
    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $APDN
    $CALT
    $GME
    $INSM
    Financials

    Live finance-specific insights

    View All

    Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026

    BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 19, 2026. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, February 19, 2026, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) an

    2/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Acquires Iverson Design Assets and Proprietary AI Design Technology Suite

    Accelerates Transformation into Tokenization and Digital Asset Platform BOSTON, MA, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)), a digital private capital markets ecosystem, today announced the acquisition of the assets of Iverson Design, LLC, a creative studio and developer of AI-powered design and visualization tools. Led by multimedia and AI designer Michael Iverson, the studio develops motion graphics, 3D product visualization, investor presentations, and immersive digital experiences. As part of the transaction, Michael Iverson joins Netcapital as Chief Design Director and Head of AI Experience. Under the agreement, Netcapital acquired Iverson Design's f

    1/6/26 4:22:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Insmed Provides Clinical and Business Update

    —Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications— BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced today that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its pri

    12/17/25 4:01:00 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $CALT
    $GME
    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Cineverse and GameStop Invite Fans to 'Return to Silent Hill' with Innovative Partnership featuring Mysterious Messages, Exclusive Rewards, In-Store Media & More

    Return to Silent Hill Hits Theaters Nationwide on January 23 – Buy Tickets Now LOS ANGELES and GRAPEVINE, Texas, Jan. 14, 2026 /PRNewswire/ -- Cineverse (NASDAQ:CNVS), a next generation entertainment studio, and GameStop Corp. (NYSE:GME), are pulling out all the stops in anticipation of the January 23 wide theatrical release of Return to Silent Hill (returntosilenthillmovie.com).  The two companies are collaborating on an immersive marketing campaign for the new film, based on the visionary video game, SILENT HILL 2. Since January 7, fans who visit a participating GameStop ca

    1/14/26 3:02:00 PM ET
    $CNVS
    $GME
    Consumer Electronics/Video Chains
    Consumer Discretionary
    Electronics Distribution

    Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

    NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a digital private capital markets ecosystem, today announced the appointment of Rich Wheeless as CEO. Former CEO, Martin Kay, will remain as an advisor to the company. Mr. Wheeless is a seasoned executive with more than 20 years of financial leadership and corporate management experience across multiple industries in both public and private enterprises. He was most recently the Chief Executive Officer of a publicly traded logistics and warehousing solutions company and has served as an active inves

    12/8/25 5:00:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $APDN
    $CALT
    $GME
    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary